1Grossman SL, Lessem J. Mechanisms and clinical effects of thiazolidinediones. Exp Opin Invest Drugs, 1997,6:1025-1040. 被引量：1
2Aronoff S, Rosenblatt S, Braithwaite S, et al. Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes : a 6-month randomized placebo-controlled dose-response study. Diabetes Care, 2000,23 : 1605-1611. 被引量：1
3Grinsell JW, Lardinois CK, Swislocki A, et al. Pioglitazone attenuates basal and postprandial insulin concentrations and blood pressure in the spontaneously hypertensitve rat, Am J Hypertens, 2000,13:370-375. 被引量：1
4Hiruse H, Kawai T, Yamamoto Y, et al. Effects of pioglitazone on metabolic parameters, body fat distribution, and serum adiponectin levels in Japanese male patients with type 2 diabetes. Metabolism,2002,51:314-317. 被引量：1
5Henry RR. Thiazolidinediones. Endocrinol Metab Clin North Am, 1997,26:553-573. 被引量：1
6Kipnes MS, Krosnick A, Rendell MS, et al. Pioglitazone hydrochloride in combination with sulfonylurea therapy improves glycemic control in the treatment of patients with type 2 diabetes: a randomized, placebocontrolled study. Am J Med, 2001,111:10-17. 被引量：1
4Khan MA, St Peter JV, Neafus KL, et al. Prospective, randomized comparison of the metabolic effects of pioglitazone vs rosiglitazone in patients with type 2 diabetes who were previously treated with troglitazone[ J]. Diabetes,2001,50( Suppl ) :219. 被引量：1
5Goldberg RB, Kendall DM, Decg MA, et al. A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia [ J ]. Diabetes Gale, 2005,28 ( 7 ) : 1547-1554. 被引量：1
6[1]Evert M,Dombrowski F.Hepatocellular carcinoma in the non-cirrhotic liver[J].Pathologe,2008,29 (1):47-52. 被引量：1
7[2]Ratziu V,Giral P,Jacqueminet S,et al.Rosiglitazone for nonalcoholic steatohepatitis:one-year results of the randomized placebo-controlled fatty liver improvement with rosiglitazone therapy(FLIRT) trial[J].Gastroenterology,2008,135(1):100-110. 被引量：1
9[7]Neuschwander-Tetri BA,Brunt EM,Wehmeier KR,et al.Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-gamma ligand rosiglitazone[J].Hepatology,2003,38(4):1008-1017. 被引量：1
10[8]Bethanis SK,Theocharis SE.Leptin in the field of hepatic fibrosis:a pivotal or an incidental player?[J].Dig Dis Sci,2006,51(10):1685-1696. 被引量：1
